ArticleCureus2025
Primary Diffuse Large B-Cell Lymphoma of the Urinary Bladder: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary urinary bladder lymphoma is a very rare disease. Hereby, we report a 53-year-old male patient who presented with sudden macroscopic hematuria. The patient had a relevant previous history of follicular non-Hodgkin lymphoma (NHL) treated initially with chemotherapy CHOP scheme and then with bendamustine-obinutuzumab, with a PET scan at the end of the treatment showing a complete response. Abdomen-pelvic tomography revealed a diffuse and irregular thickening of the bladder. In the cystoscopy, we observed multiple solid-appearing tumor lesions throughout the bladder. A biopsy was taken, with a report of diffuse high-grade large B-cell NHL. Lymphomas are a rare cause of malignant bladder tumors, with DLBCL (diffuse large B-cell lymphoma) being the least common. Given its rare presentation, there is still no standardization of the treatment; a few reports and series have been published, offering surgical, chemotherapy, or radiotherapy-guided treatment, or frequently a combination of those methods. We are still lacking more information about this condition, aiming to choose the alternative treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.